dc.contributor
[López-Jiménez T] Institut Universitari d’Investigació en Atenció Primària Jordi Gol(IDIAP Jordi Gol), Barcelona, Spain. Programa de Doctorat en Metodologia de la Recerca Biomèdica i Salut Pública, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Plana-Ripoll O] Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark. National Center for RegisterBased Research, Aarhus University, Aarhus, Denmark. [Duarte-Salles T] Institut Universitari d’Investigació en Atenció Primària Jordi Gol(IDIAP Jordi Gol), Barcelona, Spain. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands. [Palomar-Cros A, Puente D] Institut Universitari d’Investigació en Atenció Primària Jordi Gol(IDIAP Jordi Gol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain
dc.contributor
Departament de Salut
dc.contributor.author
López-Jiménez, Tomàs
dc.contributor.author
Plana-Ripoll, Oleguer
dc.contributor.author
Palomar Cros, Anna
dc.contributor.author
Puente, Diana
dc.contributor.author
Duarte-Salles, Talita
dc.date.accessioned
2026-01-28T20:30:41Z
dc.date.available
2026-01-28T20:30:41Z
dc.date.issued
2026-01-27T09:28:55Z
dc.date.issued
2026-01-27T09:28:55Z
dc.date.issued
2025-01-16
dc.identifier
López-Jiménez T, Plana-Ripoll O, Duarte-Salles T, Palomar-Cros A, Puente D. The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study. BMC Public Health. 2025 Jan 16;25(1):178.
dc.identifier
http://hdl.handle.net/11351/14198
dc.identifier
10.1186/s12889-025-21437-9
dc.identifier.uri
http://hdl.handle.net/11351/14198
dc.description.abstract
Cancer; Metabolic syndrome; Remaining life expectancy; Survival
dc.description.abstract
Càncer; Síndrome metabòlica; Esperança de vida restant
dc.description.abstract
Cáncer; Síndrome metabólico; Esperanza de vida restante
dc.description.abstract
This study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006-2017). RLE was analyzed for 13 cancer types, stratified by sex and MS components. The cohort study includes 183,364 individuals followed from diagnosis until death, transfer, or study end (December 2017). RLE at age 68 (median diagnosis age) was calculated based on MS components (0, 1, 2, and ≥ 3). Men aged 68 with 0 MS components had an RLE of 13.2 years, compared to 8.9 years for those with ≥ 3 MS. Women had an RLE of 15.9 years with 0 MS components versus 11.4 years with ≥ 3 MS. RLE varied by cancer type, with the highest RLE in men seen in prostate cancer and in women in non-Hodgkin lymphoma. The lowest RLE for both sexes was in pancreatic cancer. The largest differences between 0 and ≥ 3 MS components were observed in non-Hodgkin lymphoma and the smallest in pancreatic cancer. Increased MS components were associated with reduced RLE in at least 8 cancer types for men and 9 for women. Prevention strategies targeting MS components could increase RLE in cancer patients.
dc.description.abstract
The project was funded from the Carlos III Institute of Health, (Spain) (reference PI17/00914).
dc.format
application/pdf
dc.publisher
BioMed Central
dc.relation
BMC Public Health;25(1)
dc.relation
https://www.doi.org/10.1186/s12889-025-21437-9
dc.relation
info:eu-repo/grantAgreement/ES/ISCIII/PI17/00914
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Síndrome metabòlica
dc.subject
DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism::Insulin Resistance::Metabolic Syndrome
dc.subject
DISEASES::Neoplasms
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies
dc.subject
ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperinsulinismo::resistencia a la insulina::síndrome metabólico
dc.subject
ENFERMEDADES::neoplasias
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes
dc.title
The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
